SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia

Oncogene

Volumn 34, Issue 5, 2015, Pages 631-638

  Pasmant, E ^a,b   Gilbert Dussardier, B ^c   Petit, A ^d,e   De Laval, B ^a   Luscan, A ^a,b   Gruber, A ^a   Lapillonne, H ^e,f   Deswarte, C ^d,e   Goussard, P ^b   Laurendeau, I ^a   Uzan, B ^g   Pflumio, F ^g   Brizard, F ^c   Vabres, P ^h   Naguibvena, I ^g   Fasola, S ^d,e   Millot, F ^a,b   Porteu, F ^a,c   Vidaud, D ^a,b,c   Landman Parker, J ^d,e   Ballerini, P ^f   more..

^a INSERM   (France)

^b Institut Cochin   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d ARMAND TROUSSEAU HOSPITAL   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f Service d'Hématologie Biologique   (France)

^g Universite Paris Sud   (France)

^h UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

caf au lait spots; childhood leukaemia; Legius syndrome; neurofibromatosis type 1; SPRED1; tumour suppressor gene

Indexed keywords

MEMBRANE PROTEIN; NEUROFIBROMIN; SIGNAL PEPTIDE; SPRED1 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; BIOSYNTHESIS; CAFE AU LAIT SPOT; CHILD; COMPLICATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOSITY LOSS; HUMAN; INFANT; MALE; MUTATION; NEWBORN; ONCOGENE RAS; PATHOLOGY; PRESCHOOL CHILD; TUMOR SUPPRESSOR GENE;

ADOLESCENT; CAFE-AU-LAIT SPOTS; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; GENES, TUMOR SUPPRESSOR; HUMANS; INFANT; INFANT, NEWBORN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID, ACUTE; LOSS OF HETEROZYGOSITY; MALE; MEMBRANE PROTEINS; MUTATION; NEUROFIBROMIN 1; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 85027941829     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.587     Document Type: Article

References (32)

1. Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R et al. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet 2007; 39: 1120-1126.
2. Pasmant E, Sabbagh A, Hanna N, Masliah-Planchon J, Jolly E, Goussard P et al. SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. J Med Genet 2009; 46: 425-430.
3. Messiaen L, Yao S, Brems H, Callens T, Sathienkijkanchai A, Denayer E et al. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA 2009; 302: 2111-2118.
4. Brems H, Pasmant E, Van Minkelen R, Wimmer K, Upadhyaya M, Legius E et al. Review and update of SPRED1 mutations causing Legius syndrome. Hum Mutat 2012; 33: 1538-1546.
5. Bentires-Alj M, Kontaridis MI, Neel BG. Stops along the RAS pathway in human genetic disease. Nat Med 2006; 12: 283-285.
6. Pasmant E, Ballerini P, Lapillonne H, Perot C, Vidaud D, Leverger G et al. SPRED1 disorder and predisposition to leukemia in children. Blood 2009; 114: 1131.
7. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295-308.
8. Wakioka T, Sasaki A, Kato R, Shouda T, Matsumoto A, Miyoshi K et al. Spred is a Sprouty-related suppressor of Ras signalling. Nature 2001; 412: 647-651.
9. Nonami A, Kato R, Taniguchi K, Yoshiga D, Taketomi T, Fukuyama S et al. Spred-1 negatively regulates interleukin-3-mediated ERK/mitogen-activated protein (MAP) kinase activation in hematopoietic cells. J Biol Chem 2004; 279: 52543-52551.
10. Inoue H, Kato R, Fukuyama S, Nonami A, Taniguchi K, Matsumoto K et al. Spred-1 negatively regulates allergen-induced airway eosinophilia and hyperresponsiveness. J Exp Med 2005; 201: 73-82.
11. Stowe IB, Mercado EL, Stowe TR, Bell EL, Oses-Prieto JA, Hernandez H et al. A shared molecular mechanism underlies the human rasopathiesLegius syndrome and Neurofibromatosis-1. Genes Dev 2012; 26: 1421-1426.
12. Papaemmanuil E, Hosking FJ, Vijayakrishnan J, Price A, Olver B, Sheridan E et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet 2009; 41: 1006-1010.
13. Trevinõ LR, Yang W, French D, Hunger SP, Carroll WL, Devidas M et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet 2009; 41: 1001-1005.
14. Levine RL. Inherited susceptibility to pediatric acute lymphoblastic leukemia. Nat Genet 2009; 41: 957-958.
15. Case M, Matheson E, Minto L, Hassan R, Harrison CJ, Bown N et al. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res 2008; 68: 6803-6809.
16. Braun BS, Shannon K. Targeting Ras in myeloid leukemias. Clin Cancer Res 2008; 14: 2249-2252.
17. Bundschu K, Walter U, Schuh K. The VASP-Spred-Sprouty domain puzzle. J Biol Chem 2006; 281: 36477-36481.
18. Ishizaki T, Tamiya T, Taniguchi K, Morita R, Kato R, Okamoto F et al. miR126 positively regulates mast cell proliferation and cytokine production through suppressing Spred1. Genes Cells 2011; 16: 803-814.
19. Miyoshi K, Wakioka T, Nishinakamura H, Kamio M, Yang L, Inoue M et al. The Sprouty-related protein, Spred, inhibits cell motility, metastasis, and Rhomediated actin reorganization. Oncogene 2004; 23: 5567-5576.
20. Yoshida T, Hisamoto T, Akiba J, Koga H, Nakamura K, Tokunaga Y et al. Spreds, inhibitors of the Ras/ERK signal transduction, are disregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene 2006; 25: 6056-6066.
21. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C et al. Mutational landscape and significance across 12 major cancer types. Nature 2013; 502: 333-339.
22. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 2010; 116: 5089-5102.
23. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Mü ller C et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000; 96: 3907-3914.
24. Cutts BA, Sjogren AK, Andersson KM, Wahlstrom AM, Karlsson C, Swolin B et al. Nf1 deficiency cooperates with oncogenic K-RAS to induce acute myeloid leukemia in mice. Blood 2009; 114: 3629-3632.
25. Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, Stinson J et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010; 465: 473-477.
26. Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 2008; 22: 915-931.
27. Walter RB, Appelbaum FR, Tallman MS, Weiss NS, Larson RA, Estey EH. Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood 2010; 116: 2420-2428.
28. Lapillonne H, Llopis L, Auvrignon A, Renneville A, Labopin M, Mazingue F et al. Extensive mutational status of genes and clinical outcome in pediatric acute myeloid leukemia. Leukemia 2010; 24: 205-209.
29. Christiansen DH, Andersen MK, Desta F, Pedersen-Bjergaard J. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy related myelodysplasia and acute myeloid leukemia. Leukemia 2005; 19: 2232-2240.
30. Tartaglia M, Martinelli S, Cazzaniga G, Cordeddu V, Iavaroni I, Spinelli M et al. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 2004; 14: 307-313.
31. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
32. Letourneux C, Rocher G, Porteu F. B56-containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK. EMBO J 2006; 25: 727-738